All Search Results
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
-
EFFICACY AND COMPARISON OF TWO COMMONLY USED DOSES OF BETHANECHOL IN THE MANAGEMENT OF INFANT GASTROESOPHAGEAL REFLUX IN NEONATAL INTENSIVE CARE UNIT
EFFICACY AND COMPARISON OF TWO COMMONLY USED DOSES OF BETHANECHOL IN THE MANAGEMENT OF INFANT GASTROESOPHAGEAL REFLUX IN NEONATAL INTENSIVE CARE UNIT
-
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
-
Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
-
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
A PHASE II STUDY OF CABOZANTINIB IN COMBINATION WITH CEMIPLIMAB (REGN2810) (CABO-CEMIPLIMAB (REGN2810)) VERSUS CABOZANTINIB ALONE IN ADOLESCENTS AND ADULTS WITH ADVANCED ADRENOCORTICAL CANCER
-
ICN
Improve Care Now
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
-
Unbalanced Atrioventricular Septal Defect Study
Unbalanced Atrioventricular Septal Defect: A Congenital Heart Surgeons' Society Inception Cohort Study
-
Cystic Fibrosis National Registry
Cystic Fibrosis National Registry
-
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old With First Relapse
